Navigation Links
TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Date:9/10/2007

LA JOLLA, Calif., Sept. 10 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced completion of its third Phase I clinical trial for NGX267, in clinical development for the treatment of cognitive impairment associated with schizophrenia (CIAS). The compound, a functionally selective muscarinic (M1) agonist, was found to be safe and well-tolerated when given orally to healthy male volunteers once-daily for four consecutive days. In two previous Phase I trials, NGX267, administered as single oral doses, was shown to be well-tolerated in healthy young adult males, as well as in healthy elderly males and females.

The purpose of the Phase I trial was to investigate the safety, tolerability and pharmacokinetics of multiple doses of NGX267 and to confirm data from previous studies in which NGX267 demonstrated evidence of muscarinic receptor stimulation as measured by increases in salivary flow. A total of 60 healthy males, between the ages of 18 and 55, were enrolled in the double-blind, placebo-controlled trial conducted at one center in Belgium. In a series of sequential dosing cohorts, subjects received a single oral dose of either 10, 20, 30 or 35 mg of NGX267 once-daily for four consecutive days. NGX267 was well tolerated at doses up to and including 30 mg, a dose range believed to be effective for treating memory and cognitive disturbances. TorreyPines plans to initiate a Phase II dose-ranging trial in CIAS during the first half of 2008.

A secondary objective was to obtain quantitative measures of salivary flow, prior to and at multiple time points post-dosing, as a peripheral biomarker for stimulation of the muscarinic receptor. In the study, increases in peak and total sal
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  Atlantic Pharmaceuticals, Inc., a specialty pharmaceutical ... unique technology to deter prescription drug abuse today ... Anthony Soscia , has been chosen as ... ,s Health-Care Heroes Awards. The awards are presented ... to honor individuals and organizations demonstrating excellence and deserving ...
(Date:5/20/2013)... SAN DIEGO , May 20, 2013 ... in Elcelyx Therapeutics, Phase 2b dose-finding clinical trial of ... generic metformin, the foundational treatment for Type 2 diabetes. ... the multicenter U.S. program in June. Results of the ... are expected in late summer, and the read-out for ...
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE ... , MD, PhD, principal investigator, presented updated Phase ... cell (NSI-566) trial in the treatment of amyotrophic lateral ... disease) at the neuro diabetes special medical symposium in ... a talk called "Recent Therapeutic Advances in Stem Cell ...
Breaking Medicine Technology:Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4
... 20, 2011 TheCarrot.com , a leading ... programs, announced the immediate availability of its new ... the University of California at San Francisco,s Smoking ... behavior modification methodology with TheCarrot.com,s award-winning online and ...
... BETHESDA, Md., Jan. 20, 2011 Spherix Incorporated ... biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; ... food, supplement, biotechnology and pharmaceutical companies, today announced that ... million of shares of its common stock and warrants ...
Cached Medicine Technology:TheCarrot.com Launches Quit Smoking Program 2TheCarrot.com Launches Quit Smoking Program 3Spherix Announces Registered Direct Offering of $2.77 Million 2Spherix Announces Registered Direct Offering of $2.77 Million 3
(Date:5/20/2013)... May 20, 2013 This summer, digital ... world will make the pilgrimage to San Diego, CA, ... Digital Health Summer Summit produced by Living ... unique forum to showcase the latest digital health innovations, ... and network with some of industry’s most brilliant thinkers ...
(Date:5/20/2013)... Dennis Thompson HealthDay Reporter , , MONDAY, May ... attention deficit-hyperactivity disorder (ADHD) are twice as likely to ... disorder when they were young, a new 30-year study ... tended to have a higher body-mass index (BMI) and ... the disorder. Socioeconomics made no difference; well-off or ...
(Date:5/20/2013)... Posterior fossa subdural hematoma (PFSDH) is a serious and ... But with appropriate treatment, there,s an excellent chance of ... reports a study in the May issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , The results ...
(Date:5/20/2013)... Wolters Kluwer Health is pleased to announce ... journals won 13 ASHPE awards in 10 categories. ... publications for editorial, design, print and online award ... recognized year after year for delivering high-quality publications ... quality, depth, and impact," said Jayne Marks, Vice ...
(Date:5/20/2013)... Francisco, CA (PRWEB) May 20, 2013 ... health assistant at HealthBeat 2013. A mobile application called ... the time and effort it takes to arrange for ... Allie offers a unique combination of mobile technology and ... order to help people ensure their health care needs ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 2Health News:ADHD in Childhood May Raise Risk for Obesity in Adulthood 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Wolters Kluwer Health receives 13 awards from the ASHPE 2Health News:Allayo Debuts Virtual Health Assistant At HealthBeat 2013 2
... Nutrisystem, Inc. (Nasdaq: NTRI ), a leading developer ... new multi-year alliance with the American Diabetes Association to ... public about the importance of weight loss for people ... Nutrisystem will support the Association,s efforts to fund both ...
... 26 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH) has ... change for the Company on the OTCBB will take place ... The new ticker symbol for "CardioGenics Holdings Inc." on ... the name and ticker symbol change that is scheduled to ...
... , WASHINGTON , Oct. 26 ... Karen Ignagni, President and CEO: , "A new government-run plan would ... down costs and improve quality. The American people want health ... that. , "The divisive debate about a government-run plan ...
... LAKE FOREST, Ill., Oct. 26 Akorn, Inc. (Nasdaq: AKRX ) will release third ... conference call on Tuesday, November 10, to discuss quarterly results followed by a Q&A session: , ... Akorn Third Quarter 2009 Conference Call, Date/Time: ... ...
... the impact of severe physical, psychosocial suffering, researchers say ... survivors of World War II, those who were potentially ... cancer, likely due to physical and mental stress, an ... compared cancer rates in more than 300,000 Israeli Jews ...
... spell trouble, study finds , MONDAY, Oct. 26 (HealthDay News) ... the risk of dangerous blood clots in veins, although that ... indicates. , The 10-year study found that bigger hips are ... women but not men, while a wider waistline was associated ...
Cached Medicine News:Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 2Health News:Nutrisystem and the American Diabetes Association Form a Strategic Alliance to Promote the Importance of Weight Loss for People With Type 2 Diabetes 3Health News:AHIP Statement on Government-Run Plan 2Health News:AHIP Statement on Government-Run Plan 3Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Where You Put on Pounds May Influence Clot Risk 2
... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
... Medical's Articulating Tip Laryngoscopes are ... the Industry. The articulating tip ... providing an improved view of ... Fiber Optic styles. We guarantee ...
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
Medicine Products: